|Articles will be included if they:||
Describe the rationale for incorporating non-injectable forms of drug consumption into supervised drug consumption service models; and/or|
Discuss the existence of supervised consumption services that allow program participants to consume drugs through forms other than injection; and/or
Describe supervised consumption service models that allow program participants to consume drugs through forms other than injection (smoking, snorting, intranasal, inhalation, oral consumption, etc.); and/or
Describe the real or potential impact of allowing non-injectable forms of drug consumption within supervised drug consumption services for program participants/potential participants.
All study designs, reports, and book chapters that present or review research were eligible for inclusion.
|Articles will be excluded if they:||
Describe services or interventions related to the supervised consumption of legal drugs (e.g., tobacco, alcohol, medical cannabis, prescription drugs consumed as indicated) only; and/or|
Describe supervised consumption of drugs for the purposes of research on the physiological or behavioural effects of the drug; and/or
Describe services or interventions related to the consumption of illegal drugs (safer inhalation kits, syringe distribution, take home naloxone, etc.) but do not provide a supervised setting for consumption; and/or
Address supervised consumption of injection drugs only; and/or
Describe supervised consumption of opioid agonist treatment only (including prescription diacetylmorphine, hydromorphone, oral morphine, buprenorphine/naloxone, methadone, etc.); and/or
Are not available in English; and/or
Are conference abstracts, commentaries, editorials, letters, or media articles; and/or
Are not available publicly or through the University of Alberta holdings.